SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Nektar Therapeutics (CA) Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma